Cagrilintide 5mg

Research into cagrilintide centres on the relationship between satiety, appetite regulation and body weight. Satiety is the feeling of fullness that helps bring eating to an end. By extending the activity of an amylin analogue, cagrilintide provides a way to examine this appetite-regulating pathway over a longer period. Its molecular development established the foundation for clinical investigations of weight management. [1]

This approach has produced measurable weight reductions in human trials. In a 26-week phase 2 study of adults with overweight or obesity without diabetes, mean weight loss ranged from 6.0% to 10.8% across cagrilintide groups, compared with 3.0% for placebo, in an analysis assuming treatment adherence. These findings connect the compound’s appetite-regulating mechanism with changes in body weight. [2]

Because amylin and GLP-1 act through different receptors, researchers have also examined whether combining their activity improves outcomes. In a separate 32-week phase 2 trial in adults with type 2 diabetes, mean weight loss was 15.6% with cagrilintide plus semaglutide, compared with 8.1% for cagrilintide alone and 5.1% for semaglutide alone. These results support further investigation of complementary appetite pathways; the larger reduction was a combination-treatment finding. [3]

The trials used investigational formulations and commonly reported gastrointestinal effects, including nausea. Their results describe the studied treatments, rather than the performance of this retail batch.

References

1. Kruse et al., 2021 — Development of cagrilintide.
2. Lau et al., 2021 — Cagrilintide for weight management: phase 2 trial.
3. Frias et al., 2023 — Cagrilintide and semaglutide in type 2 diabetes: phase 2 trial.

For larger orders, visit our wholesale page to enquire about quantity pricing and availability. Include the product name and required quantity with your enquiry.

Request Wholesale Pricing